Biotechs especially have reams of acronyms and abbreviations. A critical part of coy performance is their ability to communicate clearly. Sometimes acronym soups are used to cover up but at JPMHC they are courting big players with big words, not your average punter. If VCs & potential partners see MSB as just more suits spewing acronym jumbles without commercial clarity, MSB will know about it via being ignored.
Ann: CEO Presentation at JP Morgan Healthcare Conference, page-9
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.05 |
Change
0.080(8.25%) |
Mkt cap ! $1.198B | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.06 | 99.0¢ | $4.930M | 4.779M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 23545 | $1.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.05 | 339479 | 5 |
View Market Depth
| Last trade - 16.10pm 04/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |